Nykode Therapeutics AS (OSL:NYKD)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.02B |
| Revenue (ttm) | 4.57M |
| Net Income (ttm) | -123.39M |
| Shares Out | 326.55M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.00 (31.90%) |
| Ex-Dividend Date | n/a |
| Volume | 656,186 |
| Average Volume | 1,026,365 |
| Open | 3.250 |
| Previous Close | 3.135 |
| Day's Range | 3.080 - 3.250 |
| 52-Week Range | 1.440 - 4.100 |
| Beta | 0.89 |
| RSI | 45.10 |
| Earnings Date | Apr 17, 2026 |
About Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i... [Read more]
Financial Performance
In 2025, Nykode Therapeutics AS's revenue was $453,000, a decrease of -95.05% compared to the previous year's $9.16 million. Losses were -$12.24 million, -68.47% less than in 2024.
Financial numbers in USD Financial StatementsNews
Nykode Therapeutics AS Earnings Call Transcript: Q4 2025
Q4 2025 saw strong clinical progress, notably with abisuvva's superior response rates in head and neck cancer and new patents for the VB10.NEO platform. Operating expenses fell sharply, with a solid cash runway into 2028 and key trial milestones expected in 2026-2027.
Nykode Therapeutics AS Earnings Call Transcript: Q3 2025
Advanced lead cancer immunotherapy into phase II, secured new patents for neoantigen platform, and demonstrated strong preclinical results for autoimmune tolerance. Reduced operating expenses and maintained a strong cash position, with a runway into 2028 and key data readouts expected in 2026–2027.
Nykode Therapeutics AS Earnings Call Transcript: Q2 2025
Q2 2025 saw a strategic pivot to focus on VB10.16 in head and neck cancer, with a new phase II trial planned and strong supporting data. Operating expenses dropped sharply, resulting in a net profit and a $70M cash position. Cash runway extends into 2028, supporting key inflection points.
Nykode Therapeutics AS Earnings Call Transcript: Q1 2025
Organizational streamlining and cost control improved financials, with a reduced net loss and strong cash position. Key clinical and preclinical data for VB10.16, VB10.NEO, and the immune tolerance platform support continued development, with strategic updates expected in Q2 2025.
Nykode Therapeutics AS Earnings Call Transcript: Q4 2024
Strategic refocus and cost reductions have extended the cash runway into 2030, with a strong cash position and a targeted annual cost base of $20 million. Key programs showed strong clinical and preclinical results, and the company is actively pursuing partnerships and further guidance on its pipeline.
Nykode Therapeutics AS Earnings Call Transcript: Q3 2024
A major strategic refocus will reduce costs by 50%, extend cash runway into 2030, and prioritize research and early partnerships. Clinical progress continues for VB10.16 and VB10.NEO, with strong cash and equity positions supporting the transition.
Nykode Therapeutics AS Transcript: Status Update
Genentech is terminating its VB10.NEO partnership, returning full control and IP to Nykode, with no impact from clinical data or technology issues. Nykode will explore new strategic options for VB10.NEO, maintain cost discipline, and remains confident in its pipeline and financial position.
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe
OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics AS Earnings Call Transcript: Q2 2024
Strategic focus shifted to locally advanced cervical cancer and head and neck cancer, discontinuing VB-C-04 due to recruitment challenges. Q2 net loss was $7.4M, with a strong cash position and ongoing partnerships with Genentech and Regeneron. Key U.S. patent granted for neoantigen vaccines.
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting
OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics AS Earnings Call Transcript: Q1 2024
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
Nykode Therapeutics - Quarterly report Q1 2024
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, to...
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
OSLO, Norway, March 21, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, to...
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, to...
Nykode Therapeutics AS Earnings Call Transcript: Q4 2023
Nykode Therapeutics AS Transcript: 42nd Annual J.P. Morgan Healthcare Conference
Nykode Therapeutics AS Earnings Call Transcript: Q3 2023
Nykode Therapeutics - Quarterly report Q3 2023
OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston
OSLO, Norway, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...